An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activity

Anti-Cancer Drugs

Volumn 18, Issue 2, 2007, Pages 127-137

  Miao, Qing Fang ^a   Liu, Xiao Yun ^a   Shang, Bo Yang ^a   Ouyang, Zhi Gang ^a   Zhen, Yong Su ^a,b  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Antibody; Antitumor; Enediyne energized; Fusion protein; Lidamycin

Indexed keywords

ANTIBIOTIC C 1027; ANTIBODY; COLLAGENASE; HYBRID PROTEIN; LIDAMYCIN; MITOMYCIN; MONOCLONAL ANTIBODY; VH LDP AE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXICITY; DNA RECOMBINATION; DRUG ACTIVITY; FEMALE; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR MODEL; XENOGRAFT;

ALLANTOIS; AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHICK EMBRYO; COLLAGENASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; INDICATORS AND REAGENTS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, FLUORESCENCE; MICROTUBULES; MOLECULAR SEQUENCE DATA; RECOMBINANT FUSION PROTEINS;

EID: 33845718899     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3280112779     Document Type: Article

References (46)

1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23:1147-1157.
2. Nielsen UB, Adams GP, Weiner LM, Marks JD. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res 2000; 60:6434-6440.
3. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol 2005; 23:1126-1136.
4. Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 1989; 341:544-546.
5. Cortez-Retamozo V, Lauwereys M, Hassanzadeh Gh G, Gobert M, Conrath K, Muyldermans S, et al. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer 2002; 98:456-462.
6. Davies J, Riechmann L. Antibody VH domains as small recognition units. Biotechnology (New York) 1995; 13:475-479.
7. Sievers EL. Clinical studies of new 'biologic' approaches to therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates. Curr Opin Oncol 2000; 12:30-35.
8. Hu JL, Xue YC, Xie MY, Zhang R. A new macromolecular antitumor antibiotic, C-1027. I. Discovery, taxonomy of producing organism, fermentation and biological activity. J Antibiot (Tokyo) 1988; 41:1575-1579.
9. Zhen YS, Ming XY, Yu B. A new macromolecular antitumor antibiotic, C-1027 III. Antitumor activity. J Antibiot 1989; 42:1294-1298.
10. Xu YJ, Li DD, Zhen YS. Mode of action of C-1027, a new macromolecular antitumor antibiotic with highly potent cytotoxicity, on human hepatoma BEL-7402 cells. Cancer Chemother Pharmacol 1990; 27:41-46.
11. Zhen H, Xue Y, Zhen Y. Inhibition of angiogenesis by antitumor antibiotic C1027 and its effect on tumor metastasis. Natl Med J China 1997; 77:657-660.
12. Huang YH, Shang BY, Zhen YS. Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule. World J Gastroenterol 2005; 11:3980-3984.
13. Xu YJ, Zhen YS, Goldberg IH. C1027 chromophore, a potent new enediyne antitumor antibiotic, induces sequence-specific double-strand DNA cleavage. Biochemistry 1994; 33:5947-5954.
14. Xu Y, Zhen Y, Goldberg IH. Enediyne C1027 induces the formation of novel convalent DNA interstrand cross-links and monoadducts. J Am Chem Soc 1997; 119:1133-1134.
15. Xu Y, Xi Z, Zhen Y, Goldberg IH. Mechanism of formation of novel covalent drug-DNA interstrand cross-links and monoadducts by enediyne antitumor antibiotics. Biochemistry 1997; 36:14975-14984.
16. McHugh MM, Gawron LS, Matsui S, Beerman TA. The antitumor enediyne C-1027 alters cell cycle progression and induces chromosomal aberrations and telomere dysfunction. Cancer Res 2005; 65:5344-5351.
17. Jiang B, Li D, Zhen Y. Induction of apoptosis by enediyne antitumor antibiotic C1027 in HL-60 human promyelocytic leukemia cells. Biochem Biophys Res Commun 1995; 208:238-244.
18. He QY, Liang YY, Wang DS, Li DD. Characteristics of mitotic cell death induced by enediyne antibiotic lidamycin in human epithelial tumor cells. Int J Oncol 2002; 20:261-266.
19. Wang X, Wu S, Zhen Y. Lidamycin inhibits proliferation and induces apoptosis in endothelial cells. Chin J Antibiot 2003; 28:605-612.
20. Sherman DH. New enzymes for 'warheads'. Nat Biotechnol 2002; 20:984-985.
21. Liu W, Christenson SD, Standage S, Shen B. Biosynthesis of the enediyne antitumor antibiotic C-1027. Science 2002; 297:1170-1173.
22. Ahlert J, Shepard E, Lomovskaya N, Zazopoulos E, Staffa A, Bachmann BO, et al. The calicheamicin gene cluster and its iterative type I enediyne PKS. Science 2002; 297:1173-1176.
23. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7:1490-1496.
24. Wang F, Shang B, Zhen Y. Antitumor effects of molecule-downsized imunoconjugate composed of lidamycin and Fab' fragment of monoclonal antibody directed against type IV collagenase. Sci China C Life Sci 2004; 47:66-73.
25. Li L, Huang YH, Li Y, Wang FQ, Shang BY, Zhen YS. Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma. World J Gastroenterol 2005; 11:4478-4483.
26. Sakata N, Ikeno S, Hori M, Hamada M, Otani T. Cloning and nucleotide sequencing of the antitumor antibiotic C-1027 apoprotein gene. Biosci. Biotechnol Biochem 1992; 56:1592-1595.
27. Tanaka T, Fukuda-Ishisaka S, Hirama M, Otani T. Solution structures of C-1027 apoprotein and its complex with the aromatized chromophore. J Mol Biol 2001; 309:267-283.
28. Shao RG, Zhen YS. Relationship between the molecular composition of C1027, a new macromolecular antibiotic with enediyne chromophore, and its antitumor activity. Acta Pharm Sin 1995; 30:336-342.
29. Kruger A, Arlt MJ, Gerg M, Kopitz C, Bernardo MM, Chang M, et al. Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res 2005; 65:3523-3526.
30. Rudek MA, Venitz J, Figg WD. Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy? Pharmacotherapy 2002; 22:705-720.
31. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 2005; 87:287-297.
32. Tsumoto K, Shinoki K, Kondo H, Uchikawa M, Juji T, Kumagai I. Highly efficient recovery of functional single-chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagent: application to a human single-chain Fv fragment. J Immunol Methods 1998; 219:119-129.
33. Vranken W. Solution structure of a llama single-domain antibody with hydrophobic residues typical of the VH/VL interface. Biochemistry 2002; 41:8570-8579.
34. Givol D. The minimal antigen-binding fragment of antibodies: Fv fragment. Mol Immunol 1991; 28:1379-1386.
35. Renisio JG, Perez J, Czisch M, Guenneugues M, Bornet O, Frenken L, et al. Solution structure and backbone dynamics of an antigen-free heavy chain variable domain (VHH) from Llama. Proteins: Struct, Funct, and Gen 2002; 47:546-555.
36. Worn A, Pluckthun A. Mutual stabilization of VL and VH in single-chain antibody fragments, investigated with mutants engineered for stability. Biochemistry 1998; 37:13120-13127.
37. Kortt AA, Guthrie RE, Hinds MG, Power BE, Ivancic N, Caldwell JB, et al. Solution properties of Escherichia coli-expressed VH domain of antineuraminidase antibody NC41. J Protein Chem 1995; 14:167-178.
38. Power BE, Ivancic N, Harley VR, Webster RG, Kortt AA, Irving RA, et al. High-level temperature-induced synthesis of an antibody VH-domain in Escherichia coli using the PelB secretion signal. Gene1992; 113:95-99.
39. Plückthun A. Antibodies from E. coli. Nature 1990; 347:497-498.
40. Martsev SP, Tsybovsky YI, Stremovskiy OA, Odintsov SG, Balandin TG, Arosio P, et al. Fusion of the antiferritin antibody VL domain to barnase results in enhanced solubility and altered pH stability. Protein Eng Des Sel 2004; 17:85-93.
41. Brinkmann U, Lee BK, Pastan I. Recombinant immunotoxins containing the VH or VL domain of monoclonal antibody B3 fused to Pseudomonas exotoxin. J Immunol 1993; 150:2774-2782.
42. Dubnovitsky AP, Kravchuk ZI, Chumanevich AA, Cozzi A, Arosio P, Martsev SP. Expression, refolding, and ferritin-binding activity of the isolated VL-domain of monoclonal antibody F11. Biochemistry (Moscow) 2000; 65:1011-1018.
43. Rosenblum MG, Cheung HL, Liu Y, Marks JW. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res 2003; 63:3995-4002.
44. Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 1989; 339:394-397.
45. Liu SJ, Sher YP, Ting CC, Liao KW, Yu CP, Tao MH. Treatment of B-cell lymphoma with chimeric IgG and single-chain Fv antibody-interleukin-2 fusion proteins. Blood 1998; 92:2103-2112.
46. Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L, et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002; 20:264-269.